Contact Details:
Name: Daniel Brull, CEO
Phone: +972 54 973 3280
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

BRAINWATCH Ltd.

The Clinical Need
Neurodegenerative diseases place an enormous and increasing economic burden on developed countries as their populations are aging. Current diagnosis of these diseases is essentially limited to subjective overall clinical evaluation. Large variance in clinical features and rate of disease progression between patients, together with overlapping symptoms between diseases, make the diagnostic evaluation process long and prone to errors. Furthermore, the lack of specific biomarkers impedes the development of new and effective drugs for these and other neurodegenerative diseases.

The BrainWatch Solution
BrainWatch contrast agents will allow diagnosis of neurodegenerative diseases, based on direct imaging and objective measurement of functional biomarkers. These novel contrast agents will enable rapid, accurate, specific, and objective diagnosis of these diseases at an early stage and monitoring disease progression at a later stage. By using BrainWatch's agents, physicians will be able to effectively tailor drug regimes to patients, and increase the patients' quality of life. Pharmaceutical companies will be able to use BrainWatch's contrast agents as tools for cost-effective development of disease-specific drugs.

Download Company Brochure